Medicus Pharma Ltd. (MDCXW) Cash & Equivalents (2023 - 2026)

Medicus Pharma (MDCXW) has 3 years of Cash & Equivalents data on file, last reported at $8.7 million in Q4 2025.

• Quarterly Cash & Equivalents rose 109.04% year-over-year to $8.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.7 million (up 109.04% YoY) and the FY2025 annual result came in at $8.7 million, up 109.04% from the prior year.
• Cash & Equivalents steadied at $8.7 million in Q4 2025, from $8.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $9.7 million in Q2 2025 to a low of $1.7 million in Q4 2023.
• A 3-year average of $6.2 million and a median of $6.4 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents jumped 142.21% — and 2025, when it soared 109.04%.
• Tracing MDCXW's Cash & Equivalents over 3 years: stood at $1.7 million in 2023, then surged by 142.21% to $4.2 million in 2024, then soared by 109.04% to $8.7 million in 2025.
• The last three Cash & Equivalents figures came in at $8.7 million (Q4 2025), $8.7 million (Q3 2025), and $9.7 million (Q2 2025), per Business Quant data.